| Identification | Back Directory | [Name]
Pulmozyme | [CAS]
143831-71-4 | [Synonyms]
Pulmozyme
Unii-953A26oa1y
Dnase1 protein, human
Deoxyribonuclease I recombinant human form
1: PN: WO2007027578 PAGE: 17 claimed protein
Deoxyribonuclease (human clone 18-1 protein moiety)
Nuclease, deoxyribo- (human clone 18-1 protein moiety) | [MDL Number]
MFCD04113356 |
| Hazard Information | Back Directory | [Description]
Dornase alfa, the highly purified solution of recombinant human
deoxyribonuclease I (rhDNase) produced by genetic engineering technology, was
launched in 1994 first in the U.S.A. and shortly after in 7 other countries as the first
new drug released in 30 years for the treatment of cystic fibrosis. Dornase alfa is
effective in liquefying secretions from the lungs of cystic fibrosis patients by
cleaving the extracellular DNA in purulent sputum and therefore reducing the
viscoelasticity of the secretion. It also lessens dyspnea, improves lung function,
reduces cough severity and frequency, increases the perception of well-being for
the patients with cystic fibrosis related symptoms, and has excellent safety profile.
Significant benefits have been reported in trials for the treatment of chronic
obstructive pulmonary disease and acute infectious exacerbation of chronic
bronchitis. | [Originator]
Genentech (U.S.A.) | [Uses]
Cystic fibrosis therapy adjunct. | [Brand name]
Pulmozyme (Genentech). |
|
|